The fidelity factor: evaluating the promise and pitfalls of synthetic DNA as a drug substance

“...prioritizing sequence fidelity where it matters most will be essential to unlocking the full potential of genetic medicine...”

Cell-free DNA synthesis platforms offer speed advantage over cell-based production, but their capacity to meet the sequence fidelity demands of genetic medicines warrants scrutiny. In living systems, multilayered error-correction mechanisms substantially reduce mutation frequency — an advantage absent in vitro. Comparative data demonstrate that enzymatic amplification methods generate more deleterious variants than Escherichia coli derived DNA. For constructs requiring durable or irreversible genetic modification, even low error rates carry meaningful clinical risk. Therefore, rigorous validation and orthogonal quality controls are essential when adopting cell-free platforms for therapeutic applications with stringent fidelity requirements.

Please enter your email to access content Read now